Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27260 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seeing something new or with new eyes?
Br J Haematol
September 2025
Nuffield Department of Population Health, University of Oxford, Oxford, UK.
When a new phenomenon is reported, despite many previous reports on larger cohorts of patients, one naturally asks why the finding is novel. Is this a new phenomenon, or merely identified because one is looking carefully for it for the first time? This commentary explores possible reasons for the novel finding of essential thrombocytopenia emerging in a cohort of Nucleophosmin 1 (NPM1)-mutated acute myeloid leukaemia (AML) patients. Commentary on: Bertoli et al.
View Article and Find Full Text PDFResidual disease in NPM1-mutated acute myeloid leukemia.
Clin Chim Acta
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical, Tehran, Iran. Electronic address:
Acute myeloid leukemia (AML) represents a genetically heterogeneous malignancy, with mutations in the nucleophosmin-1 (NPM1) gene identified as the most prevalent and clinically significant molecular biomarkers. These mutations play a crucial pivotal role in the realms of diagnosis, prognosis, and therapeutic decision-making. Although an ideal measurable residual disease (MRD) test has yet to be developed, there is increasing acknowledgment of the significance of advanced molecular methodologies for monitoring MRD in NPM1-mutated (NPM1) AML.
View Article and Find Full Text PDFA Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia.
Cancers (Basel)
August 2025
Department of Medicine, Division of Hematology/Oncology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA.
This study investigates genomic alterations (GA) between NPM1-mutated (NPM1mut) and wild-type (NPM1wt) acute myeloid leukemia (AML), aiming to better understand the AML genomic profile. NPM1mut AML represents a distinct clinical AML subtype with high relapse rates despite initial responsiveness to chemotherapy. A total of 4206 AML cases from 2019 to 2024 were analyzed using the FoundationOne Heme assay, incorporating comprehensive DNA and RNA sequencing.
View Article and Find Full Text PDFOutcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.
Am J Hematol
August 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The role of menin inhibitors in acute myeloid leukemia.
Curr Opin Oncol
August 2025
Hematology Unit, Ospedale S. Maria delle Croci, Ravenna (RA), Italy.
Purpose Of Review: Acute myeloid leukemia (AML) characterized by NPM1 mutations or KMT2A rearrangements depends on abnormal epigenetic programs mediated by menin, a critical scaffold protein for sustaining the expression of oncogenic HOX/MEIS1 genes. Therefore, menin inhibitors have become a promising class of AML treatments.
Recent Findings: Early-phase trials have shown that agents such as revumenib, ziftomenib, bleximenib, and enzomenib are active, particularly in relapsed/refractory disease, with 23-48% of patients achieving composite complete remission.